EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies

Yuji Kumagai iD, Tomoe Fujita iD, Mika Maeda iD, Akiko Yamamoto iD, Hideki Amano iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70039 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Yuji Kumagai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kitasato University Hospital, Kanagawa, Japan. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Taiho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

TAS5315 is a Bruton tyrosine kinase (Btk) inhibitor in development for autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). Two clinical studies evaluated the pharmacology and safety of single and multiple oral doses of TAS5315.

Methods

Two phase 1 studies (single ascending‐dose [SAD] and multiple ascending‐dose [MAD]) assessed the pharmacokinetics (including effect of food), pharmacodynamics (Btk occupancy, inhibition of basophil activation) and safety of TAS5315 (up to 8 mg/day) in healthy males.

Results

TAS5315 showed linear pharmacokinetics over a 0.01‐8 mg dose range; maximum plasma concentration and area under the plasma concentration‐time curve were reduced by ~40% by food. TAS5315 had dose dependent effects on Btk and basophil activation. In the SAD study, doses ≥2 mg resulted in mean Btk occupancy of almost 100% at 2 and 6 h, and >80% at 24 h, post‐administration. TAS5315 1‐8 mg/day inhibited basophil activation (mean change from baseline −55% to −89%). TAS5315 was generally tolerable. Although it dose‐dependently reduced platelet aggregation (over 2‐8 mg in both studies) and prolonged bleeding time (1‐8 mg in the MAD study), no relationship between these effects and clinical symptoms was observed. All adverse drug reactions were mild and resolved without treatment; no noteworthy safety concerns were observed in either study.

Conclusion

These data indicate TAS5315 has potential as a novel therapeutic for immunological diseases associated with aberrant Btk signalling, including RA and CSU. Further evaluation of TAS5315 is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsHumansMaleAdultDose-Response Relationship, DrugYoung AdultMiddle AgedHealthy VolunteersFood-Drug InteractionsBasophilsAdministration, OralArea Under CurveTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Bruton tyrosine kinaseTAS5315basophil activationchronic spontaneous urticariarheumatoid arthritis

Substanzen

Agammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Kitasato University Hospital, Kanagawa, Japan.
  • Clinical Trial Center, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.
  • Department of Pharmacology and Toxicology, School of Medicine, Dokkyo Medical University, Tochigi, Japan.
  • Laboratory of Clinical Pharmacoepidemiology and Research and Education Center for Clinical Pharmacy, School of Pharmacy, Kitasato University, Kanagawa, Japan.

ORCID-Profile: Yuji Kumagai, Tomoe Fujita, Mika Maeda, Akiko Yamamoto, Hideki Amano

Förderung

  • Taiho Pharmaceutical Co., Ltd.

Zitieren

APA

Kumagai, Y., Fujita, T., Maeda, M., Yamamoto, A., & Amano, H. (2025). Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70039

Vancouver

Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H. Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70039

BibTeX
@article{Kumagai2025,
  author = {Kumagai, Yuji and Fujita, Tomoe and Maeda, Mika and Yamamoto, Akiko and Amano, Hideki},
  title = {Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70039}
}
Kostenlos starten →